Here, we performed an extensive profiling of systemic myeloid cell populations and plasma soluble factors in NSCLC patients undergoing PD‐L1/PD‐1 blockade therapies, before and during treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.